MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    Donepezil for mild cognitive impairment in Parkinson’s disease: A 48-week follow-up study

    K. Baik, S. Kim, S. Kang, Y. Sohn, P. Lee, S. Kang (Seoul, Republic of Korea)

    Objective: To investigate the efficacy of donepezil for mild cognitive impairment (MCI) in Parkinson’s disease (PD). Background: MCI is common in PD. The mechanism of…
  • MDS Virtual Congress 2020

    Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Impact on Impulse Control Disorders

    A. Espay, K. Markopoulou, P. Bhargava, B. Navia (Cincinnati, OH, USA)

    Objective: Evaluate effect of apomorphine sublingual film (APL-130277; APL) on impulse control disorders (ICD) in patients with Parkinson’s disease (PD) and “OFF” episodes. Background: In…
  • MDS Virtual Congress 2020

    Long term safety of levodopa/carbidopa infusion with ND0612: Results from a phase 2b, international, open-label study

    S. Isaacson, W. Poewe, T. Simuni, O. Rosenfeld, R. Case, T. Yardeni, W. Olanow (Boca Raton, FL, USA)

    Objective: The primary objective of this long-term study was to evaluate the safety and tolerability of a 24-hour regimen and a 16-hour ‘waking day’ regimen…
  • MDS Virtual Congress 2020

    Interpretation of health-related quality of life outcomes from the EARLYSTIM Study

    P. Martinez-Martin, G. Deuschl, L. Tonder, A. Schnitzler, J.L Houeto, J. Rau, C. Schade-Brittinger, V. Stoker, M. Vidailhet, P. Krack (Madrid, Spain)

    Objective: To conduct a secondary analysis of the EARLYSTIM study1 to 1: Quantify the meaning of HRQoL outcomes and 2: Evaluate the changes of disease…
  • MDS Virtual Congress 2020

    Real Time Quality Control for Subjective Endpoints in Clinical Trials

    Y. Peng, G. Morinan, J. O'Keeffe (London, United Kingdom)

    Objective: Here we present a system which is capable of performing nearly-real time monitoring of UPDRS part-3 motor assessments using a combination of multidimensional statistics…
  • MDS Virtual Congress 2020

    Dose Optimization of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients with Parkinson’s Disease: Clinical and Exposure Response Findings

    F. Stocchi, C. Olanow, E. Peckham, F. Agbo, Y. Chiu, K. Sciarappa, B. Navia (Rome, Italy)

    Objective: Evaluate if dose optimization (DO) of apomorphine sublingual film (APL-130277; APL) can achieve improved FULL “ON” response in patients with Parkinson’s disease (PD) and…
  • MDS Virtual Congress 2020

    Postmenopausal hormone therapy and Alzheimer’s disease, dementia, and Parkinson’s disease: A systematic review and time-response meta-analysis

    M. wu, M. Ye (Nanjing, China)

    Objective: The study aim was to determine the relation between menopausal hormone therapy and Alzheimer's disease, dementia, and Parkinson's disease in human subjects. Background: We…
  • MDS Virtual Congress 2020

    Combined therapy VS only levodopa therapy in a 5-years follow up cohort

    C. Borrue-Fernandez, J. Alvarez -Alberca (San Sebastian Reyes, Spain)

    Objective: Describe the frequencies of appearance of motor fluctuations, impulse control disorders, in two therapeutic regimes: combined therapy (levodopa plus an other antiparkinsonian drug) or…
  • MDS Virtual Congress 2020

    Efficacy of opicapone compared to entacapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations: A post-hoc conservative analysis

    J. Ferreira, A. Lees, G. Ebersbach, A.T Santos, D. Magalhães, J.F Rocha, P. Soares-da-Silva (Lisbon, Portugal)

    Objective: To assess the efficacy of opicapone 50 mg (OPC 50 mg), compared with entacapone (ENT), in catechol-O-methyltransferase inhibitor (COMTi)-naïve Parkinson’s disease (PD) patients recently…
  • MDS Virtual Congress 2020

    Calcitriol Treatment Attenuates Dopaminergic Neurodegeneration in Mice Model of Parkinson’s Disease

    JJ. Hu, T. Wang (Wuhan, China)

    Objective: To investigate the role and mechanism of Calcitriol (1,25-dihydroxyvitamin D3) in Parkinson's mice and cell model Background: Parkinson's disease (PD) is a neurodegenerative disorder…
  • « Previous Page
  • 1
  • …
  • 55
  • 56
  • 57
  • 58
  • 59
  • …
  • 149
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley